title: [Antihypertensive treatment and remission of left ventricular hypertrophy. Critical study].
abstract: Left ventricular hypertrophy which is the adaptive mechanism of the heart to hypertension may become a cardiovascular risk factor independent of the hypertension which induced it: the regression of left ventricular hypertrophy therefore constitutes one of the medium-term objectives of antihypertensive therapy. Some antihypertensive drugs make the left ventricular hypertrophy regress early and permanently: methyldopa, betablockers, converting enzyme inhibitors, calcium antagonists. The reduction of myocardial mass is slight or debatable with diuretics and absent or inconstant with vasodilator therapy. The regression of left ventricular hypertrophy in hypertension raises several problems: the reliability of methods of measurement; inter-individual and inter-drug variations; the beneficial nature of this regression; the preventive effect of regression of left ventricular hypertrophy on cardiovascular complications. In the light of recent trials, early treatment of hypertension may prevent the development of left ventricular hypertrophy.
authors: Service de cardiologie, hôpital Cardiologique, université de Bordeaux, Pessac.
authors: J
authors: J
authors: Clémenty
authors: M N
authors: MN
authors: Dulhoste
authors: P
authors: P
authors: Bordier
authors: M C
authors: MC
authors: Lartigue
authors: N
authors: N
authors: Pons
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004341:Drug Evaluation; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology
chemical_list: D000959:Antihypertensive Agents
vernacular_title: Traitement antihypertenseur et régression de l'hypertrophie ventriculaire gauche. Etude critique.